ClinicalTrials.gg

Program

Chlorhexidine

Also written as “chlorhexidine (CHX)”, “Chlorhexidine 2.5 mg” and “chlorhexidine/lidocaine”.

Its studies are mostly in Peri-Implantitis · Pharyngitis, led by 3 companies.

Furthest: phase 3, since Jun 27, 20083 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
A. Vogel10 open or runningphase 3since Jun 27, 2008Jun 27, 2008none ahead
Biointelligent Technology Systems SL10 open or runningno phasesince May 4, 2026May 4, 2026none ahead
Dexcel Pharma Technologies10 open or runningphase 2since Mar 2, 2010Mar 2, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 27, 2008First study: phase 3 study in PharyngitisNew to A. VogelA. Vogel · NCT00707902 · 154 enrolled · Switzerland
  2. Mar 2, 2010Dexcel Pharma Technologies's first study: phase 2 study in Peri-ImplantitisNew to Dexcel Pharma TechnologiesDexcel Pharma Technologies · NCT01079663 · 60 enrolled · Israel
  3. May 4, 2026Biointelligent Technology Systems SL's first study: no phase study in Tooth Extraction Site HealingNew to Biointelligent Technology Systems SLBiointelligent Technology Systems SL · NCT07611123 · 94 enrolled · Saudi Arabia

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cell membrane inhibitor”ChEMBL 37, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07611123Tooth Extraction Site Healing · Saudi Arabia–CompletedBiointelligent Technology Systems SLMay 10, 202694
NCT01079663Peri-Implantitis · Israel2CompletedDexcel Pharma TechnologiesOct 201160
NCT00707902Pharyngitis · Switzerland3CompletedA. Vogel154

How it is read

Names in the registry

  • “chlorhexidine (CHX)”, 1 entry
  • “Chlorhexidine 2.5 mg”, 1 entry
  • “chlorhexidine/lidocaine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.